Elegen, a leader in cell-free synthetic DNA production, announced today the commercial launch of an enhancement to Enfina DNA that provides researchers with a reliable supply of very high complexity DNA in as fast as 10 business days. This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.

The company had a tremendous response to its Early Access Program (EAP) for high-complexity DNA, announced in late May 2023. EAP partners received long and very complex DNA sequences that were either rejected by other suppliers or would have taken months to synthesize.

Orbital Therapeutics, an early-stage company focused on integrating transformative technologies to drive RNA-based medicine advances, participated in Elegen's EAP. "We tested variations of complex constructs for mRNA synthesis,” said Raghav Poudyal, Ph.D., Associate Director of RNA process development at Orbital Therapeutics.

“Receiving these molecules in a matter of weeks has helped us save a considerable amount of time during the development of a new mRNA therapeutic." Gilles Besin, Ph.D., Chief Scientific Officer at Orbital, continued, “Elegen's unique expertise in supplying long, accurate, very complex IVT-ready synthetic DNA constructs is very attractive to us. By leveraging Elegen’s platform, we see the opportunity to accelerate the development of our novel mRNA therapies. We're excited to continue partnering with them.”

“Providing our customers with very complex DNA that is notoriously difficult to synthesize in a matter of days enables them to explore a broader sequence space much faster,” said Matt Hill, Ph.D., founder and CEO of Elegen. “This upgrade to our offering reflects our commitment to pushing the boundaries of DNA manufacturing innovation and underscores our dedication to provide researchers with the tools they need to accelerate scientific innovations."